Analyst Price Targets — SGHT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 28, 2026 12:04 pm | — | UBS | $7.00 | $5.33 | TheFly | Sight Sciences resumed with a Buy at UBS |
| March 2, 2026 1:19 pm | — | Cantor Fitzgerald | $8.00 | $5.44 | StreetInsider | Sight Sciences Inc. (SGHT) PT Raised to $8 at Stifel Following Optometrist Survey |
| January 5, 2026 10:56 am | Matt O'Brien | Piper Sandler | $9.00 | $7.48 | TheFly | Sight Sciences upgraded to Overweight from Neutral at Piper Sandler |
| January 5, 2026 8:54 am | — | Raymond James | $9.00 | $7.48 | StreetInsider | Piper Sandler Upgrades Sight Sciences Inc. (SGHT) to Overweight |
| December 23, 2025 12:54 am | — | UBS | $12.00 | $8.44 | TheFly | Sight Sciences price target raised to $12 from $7 at UBS |
| December 10, 2025 1:58 pm | — | Lake Street | $12.00 | $8.47 | TheFly | Sight Sciences price target raised to $12 from $7 at Lake Street |
| December 2, 2025 11:38 am | Patrick Wood | Morgan Stanley | $8.00 | $8.17 | TheFly | Sight Sciences price target raised to $8 from $6 at Morgan Stanley |
| October 21, 2025 12:43 pm | — | Lake Street | $7.00 | $4.57 | TheFly | Sight Sciences price target raised to $7 from $5 at Lake Street |
| June 18, 2025 10:50 am | Matt O'Brien | Piper Sandler | $4.00 | $4.27 | TheFly | Sight Sciences price target raised to $4 from $3.50 at Piper Sandler |
| March 6, 2025 12:00 pm | — | Stifel Nicolaus | $4.00 | $2.49 | TheFly | Sight Sciences price target lowered to $4 from $5 at Stifel |
Latest News for SGHT
MENLO PARK, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced that it will present at the upcoming Morgan Stanley Global Healthcare Conference in New York, NY.
MENLO PARK, Calif., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative interventional technologies intended to transform care and improve patients' lives, today announced that, effective August 18, 2026, the U.S. Food and Drug Administration (FDA) updated the TearCare® System (TearCare) Indications for Use to state:
Sight Sciences, Inc. (SGHT) Q2 2026 Earnings Call Transcript
Sight Sciences NASDAQ: SGHT reported second-quarter revenue growth of 20% year over year, supported by gains in its interventional glaucoma and interventional dry eye businesses, while reducing operating expenses and cash usage. The company raised its full-year revenue outlook and lowered its adjusted operating expense guidance.
Sight Sciences (NASDAQ: SGHT) reported second-quarter revenue growth of 20% year over year, supported by gains in its interventional glaucoma and interventional dry eye businesses, while reducing operating expenses and cash usage. The company raised its full-year revenue outlook and lowered its adjusted operating expense guidance. Total revenue for the quarter ended June 30 was $23.4
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for SGHT.
U.S. House Trading
No House trades found for SGHT.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.